INTRODUCTION
The oral cavity, an organ important for humans to live rich lives, has a complicated structure including the teeth. If cancer arises in the oral cavity, it markedly impairs the quality of life. Oral cancers are integrated in head and neck cancers and are applied to the general rules on head and neck cancer, but it is considered that more detailed rules based on the characteristics of oral cancers are essential. This is why we authored the 'General Rules for Clinical and Pathological Studies on Oral Cancer'. These rules were formulated on the basis of the UICC and WHO classifications, in principle, but they were partially revised when revision was considered necessary and were proposed as a draft by the Japan Society for Oral Tumors.
We already published the Japanese edition (1) originally in 2010 and it consisted of three parts, i.e. the overview, rules and explanations, totaling 102 pages. In this paper, the English edition of the 'Rules' section is primarily presented because of space limitation.
OBJECTIVES
For people handling oral cancers in various positions to be able to conduct diagnosis, treatment and research with a common perception, the standardization of basic concepts and specific methods for their handling is necessary. The objectives of these rules are to collect clinical, surgical and pathological findings including image information by employing common standards, clarify detailed pathological features, accumulate useful medical information from individual patients at various facilities and contribute to the development of the diagnosis, treatment and research of oral cancers.
TARGET DISEASES
In the present rules, oral cancers mean carcinomas originating in the covering mucosa at six sites in the oral cavity according to the UICC classification. They are targeted to: (1) tongue cancer, (2) upper gingival cancer, (3) lower gingival cancer, (4) buccal mucosal cancer, (5) oral floor cancer and (6) hard palate cancer in the order of incidence, and secondary cancers are excluded. Cancer of the salivary gland is dealt with as a separate item. Distance from the surface of the imaginary normal mucosa to the deepest part of cancer invasion In the present rules, original evaluation criteria were prepared for the invasion of adjacent tissues (T4a) by attaching importance to evaluation of the depth. 
REGIONAL LYMPH NODE METASTASIS
The classification and range of cervical lymph nodes are the same as described in the Rules Regarding Lymph Nodes by the Japan Society of Clinical Oncology (JSCO), and lymph node metastasis was evaluated according to the UICC classification. Internationally, the level classification system by ACHNSO based on the area of neck dissection is widely used, and the AAO-HNS classification, a fragmented version of the ACHNSO classification, has also been proposed.
(1) Site Regional lymph node groups (JSCO), Level classification (AAO-HNS) (2) Number of metastasis Number of metastatic lymph nodes (3) Size (,3,6,) cm (4) Adhesiveness (2/þ) Extranodal invasion (2/þ) (5) N factor cN NX: Regional lymph nodes cannot be assessed N0: No regional lymph node metastasis N1: Metastasis in a single ipsilateral lymph node, 3 cm in greatest dimension N2a: Metastasis in a single ipsilateral lymph node, .3 cm but 6 cm in greatest dimension N2b: Metastasis in multiple ipsilateral lymph nodes, none .6 cm in greatest dimension N2c: Metastasis in bilateral or contralateral lymph nodes, none .6 cm in greatest dimension N3: Metastasis in a lymph node, .6 cm in greatest dimension ,Level classification. ( Tis  0   T1  I  III  IVA  IVB  IVC   T2  II  III  IVA  IVB  IVC   T3  III  III  IVA  IVB  IVC   T4a  IVA  IVA  IVA  IVB  IVC   T4b  IVB  IVB  IVB  IVB  IVC 
ORAL PRECANCEROUS LESIONS
Since oral cancers are often accompanied by oral precancerous lesions such as leukoplakia and erythroplakia, their sites, sizes, surface properties, number, whether they are synchronous or heterochronous etc. are recorded.
CONDITIONS OF THE ORAL CAVITY
State of oral hygiene: good/poor Teeth and prosthetics related to the primary lesion: absent/ present
(1) State of fit: good/poor (2) Sharp edges: absent/present (3) Lingual inclination or displacement: absent/present (4) Edging into the mucosa: absent/present (5) Type of dental prosthesis ( ) (6) Periodontal disease: absent/present (severe/moderate/ mild) (7) Impacted/half-impacted teeth: absent/present Surgical procedures at the lesion site such as tooth extraction and incision: absent/present (contents of treatment) Motor/sensory/gustatory disorders (1) Trismus: absent/present (distance of mouth opening mm) (2) Motor disorders: absent/present (site) (3) Sensory disorders: absent/present (site) (4) Gustatory disorders: absent/present
LIFESTYLE
Individual lifestyle is very significant as a risk factor of oral cancer. Particularly, smoking and drinking are major risk factors of cancer. Therefore, the lifestyle history is recorded in consideration of the risk of recurrence and double cancers.
Regarding smoking, whether the patient is a smoker or non-smoker is indicated. The amount of smoking is expressed as the product of the mean number of cigarettes smoked per day and the number of years of smoking (Brinkman index). The amount of drinking is also expressed as the product of the mean daily amount of drinking (in ml of sake or ounces of alcohol) and the number of years or drinking (Sake index etc.). † Brinkman index ¼ mean number of cigarettes smoked per day Â number of smoking years † Sake index ¼ mean amount of drinking per day (in ml of sake) Â number of drinking years ,Scales for conversion into ml of sake. 180 ml of sake ¼ a large bottle of beer (633 ml) ¼ 2 single glasses of whisky (70 ml) ¼ 90 ml of shochu (distilled spirit) ¼ 2 glasses of wine (220 ml)
BIOPSY
In performing biopsy with the expectation of treatment, cancer tissue together with adjacent non-cancerous mucosa is generally sampled by wedge resection. The objective of biopsy is not only to make a definitive diagnosis of cancer, but also to obtain detailed information concerning the degree of histological malignancy, invasion pattern, vascular infiltration and probability of lymph node metastasis. It is desirable to collect a tissue block 5 mm or larger in long diameter containing the margin of invasion by biopsy. If a wide non-stained area is observed around the cancer by iodine vital staining, information useful for the determination of the resection margin can be obtained by further collecting tissue samples containing both stained and non-stained areas.
If the lesion is an early and small cancer (early T2 or less advanced) on careful examination of its depth by palpation and imaging, mucosal resection of an area containing the entire iodine non-stained area is also recommended.
II. RECORDING OF INTRAOPERATIVE FINDINGS AND THOSE ON GROSS EXAMINATION OF THE RESECTED SPECIMENS

SURGICAL PROCEDURE
The matters entered into the operation record should be illustrated in detail. Whether reconstruction was performed and the construction procedure, intraoperative complications, radicality of the procedure and postoperative course should also be recorded. 
III. HANDLING OF SURGICAL SPECIMENS
SECTIONING METHOD
It is a principle of surgical pathological studies of mucosal cancer to prepare cross-sections perpendicular to the mucosal surface.
1) Sampling of soft tissues of the tongue, buccal mucosa and floor of the mouth
In cancers of the tongue, buccal mucosa and floor of the mouth, examination of coronal sections is preferably recommended.
Sections are obtained at intervals of 5 -7 mm by step sectioning, and tumoral and ulcerative lesions in each section are photographed as magnified images.
Large samples containing the skin, muscle or bone tissue are sectioned at intervals of 1 -2 cm and photographed after checking the spread of the tumor on the mucosal surface and depth. Subsequently, a tissue block of 4 -5 mm thick is sectioned from a representative cross-section to prepare specimens.
2) Sampling of maxillary or mandibular gingival cancer (1) Surgical sample consisting of soft tissues alone After checking the extent of the lesion ( particularly, the anteroposterior dimension, lateral margins, gingival margin at the dental neck adjacent to the next tooth), the sample is sectioned coronally or sagittally by referring to image
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General rules on oral cancer information such as computed tomography and magnetic resonance imaging. In sectioning, the resection margin is first sectioned, the center of the primary lesion is sectioned next and serial sections are obtained at intervals of 4-5 mm.
(2) Surgical samples containing hard tissues (a) Method to examine the sample without separating hard and soft tissues The basic method to section samples of upper or lower gingival cancer containing tooth or bone tissue is to section them perpendicularly to the dental arch centering around the deepest part of the primary tumor. If the tumor is located in the incisor region, the dental arch is markedly curved, so the sample should be sectioned radially.
As the lateral and molar regions are also arched gently, sections should be made by checking the direction of the teeth. Sections containing hard tissue are cut out at intervals of 7 -8 mm using a diamond cutter and decalcified after photographing the cross-sections. (b) Method to examine the sample by separating soft tissue and bone Since the stainability of soft tissue is expected to be reduced by the decalcification of bone, specimens may also be prepared after separating hard and soft tissues. By employing this method, accurate diagnosis is impossible unless the spatial relationship between bone and soft tissue is clear. Their locations must be determined using photographs etc., and the spatial relationships of invasion sites and the resection margin should be clarified, before the separation. In mandibular gingival cancer, since tumor cells are present more often in the margin of soft tissue rather than bone, judgment using high-quality specimens is meaningful. Particularly, in patients who have undergone preoperative treatments such as chemotherapy, the judgment of the therapeutic effect is often difficult using decalcified soft tissue specimens.
DECALCIFICATION METHODS
Tissue sections 7 -8 mm thick containing hard tissue are placed in a decalcification solution after washing under running water or without washing or after defatting in a mixture of equal volumes of methanol and chloroform for 1 day as a pretreatment. Usually, Plank-Rychlo's rapid decalcification solution is used. The stainability after decalcification is preserved by performing low-temperature decalcification in a refrigerator (low-temperature decalcification). A sufficient amount of decalcification solution for the sample (several tens of times) should be prepared and changed during the decalcification process when considered appropriate. Also, decalcification is accelerated by shaking the decalcification solution. EDTA decalcification solution Oral type Tis cancer has been known as a cancer that develops into squamous cell carcinoma other than CIS based on the WHO diagnostic criteria. This is squamous intraepithelial neoplasia, a tumor that retains the maturation and differentiation characteristics of the stratified squamous epithelium. In the present rules, the term OIN is used to avoid confusion with the conventional (WHO) diagnostic criteria for CIS and to indicate that the tumor is characteristically an oral lesion. If radiation therapy or chemotherapy has been conducted against oral cancer, conditions of treatment including the dose of radiation, irradiation method, kinds, doses and administration methods of the drugs used, and time from the last treatment to resection of the lesion should be recorded.
In examining patients after preoperative treatment, specimens of the grossly estimated lesion must be prepared as much as possible, and the state of the remaining tumor must be evaluated histologically. At the time of evaluation, the conditions of the target and non-target lesions are described, and the evaluation results and judgments are recorded.
OTHER TREATMENTS
Hyperthermia, laser treatment, cryosurgery etc., are recorded to the maximum detail including the instruments used and procedures as surgical, radiation and drug therapies. If alternative therapies have been conducted, they should also be recorded.
CLINICAL EVALUATION OF THERAPEUTIC EFFECTS
By respecting the intent of the Evaluation Criteria for Direct Effects of Chemotherapy against Solid Cancers by the Japan Society of Clinical Oncology, and in consideration of the organ specificity of head and neck and oral cancers, the Evaluation Criteria for Therapeutic Effects have been adopted. Internationally, however, the Response Evaluation Criteria in Solid Tumors (RECIST) Guideline was published in 2000 as a revision of the WHO criteria and also adopted by the Japan Society of Clinical Oncology. Therefore, this guideline is also applied to oral cancers, but, as it is not a specific guideline for oral cancer, some consideration is necessary in its evaluation. The evaluation criteria are designed to evaluate the effects of non-surgical treatments including not only preoperative treatments but also chemotherapy, radiation therapy and immunotherapy. ,Outline of the RECIST, JCOG edition.
(1) Complete response (CR): disappearance of all target lesions (2) Partial response (PR): a 30% or greater decrease in the sum of long diameters of the target lesions compared with the baseline level (3) Stable disease (SD): a decrease in the tumor size insufficient to be classified as PR and an increase in the tumor size compared with the minimum sum of long diameters after the beginning of treatment insufficient to be classified as PD (4) Progressive disease (PD): a 20% or greater increase in the sum of long diameters of the target lesions compared with the minimum recorded after the beginning of treatment
To judge the response as CR or PR, fulfillment of the criteria for CR or PR should be confirmed on reevaluation 4 or more weeks after the initial fulfillment of the criteria. In some studies, setting a longer interval by the protocol may be appropriate. SD is defined by the protocol. The criteria for SD should be met at least once beyond a minimum period after registration of the study (generally 6 -8 weeks or longer). The response rate is calculated by counting CR and PR alone as positive responses.
VI. THERAPEUTIC RESULTS 
POSTOPERATIVE COURSE
